Skip to main content
OpenTrials

Clinical trial condition

Primary Immunodeficiency Diseases

Explore clinical trials studying Primary Immunodeficiency Diseases. Study availability and eligibility vary by location and protocol.

161 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Primary Immunodeficiency Diseases trial results

Completed

Gammagard Liquid and rHuPH20 in PID

NCT00814320

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Cypress, California, United States
  • Irvine, California, United States
  • Los Angeles, California, United States
  • San Francisco, California, United States
View all 14 locations
View Trial Details
Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

NCT00546871

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Los Angeles, California, United States
  • Centennial, Colorado, United States
  • North Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
View Trial Details
Completed

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • University of California, Irvine Irvine, California, United States
  • IMMUNOe International Research Centers Thornton, Colorado, United States
  • Allergy Associates of the Palm Beaches, PA North Palm Beach, Florida, United States
  • LSU Health Sciences Center & Children´s Hospital New Orleans, Louisiana, United States
View Trial Details
Completed

Immune Globulin Subcutaenous (Human), 20%

NCT01412385

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Medizinische Universität Wien / AHK Wien (General Hospital Vienna), Universitätsklinik für Kinder- und Jugendheilkunde Vienna, Austria
  • Universitätsklinikum Erlangen, Medizinische Klinik 3 Erlangen, Germany
  • University Medical Centre Freiburg, Centre of Chronic Immunodeficiency, Divison of Rheumatology and Clinical Immunology Freiburg im Breisgau, Germany
  • Universitätsklinikum Hamburg-Eppendorf, Kinderklinik Hamburg, Germany
View Trial Details
Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

NCT00782106

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • First Allergy and Clinical Research Center Centennial, Colorado, United States
  • Allergy Associates of the Palm Beaches North Palm Beach, Florida, United States
  • Pediatrics Allergy/Immunology Association, PA Dallas, Texas, United States
View Trial Details
Completed

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

NCT01581593

Conditions
Agammaglobulinemia, Antibody Deficiency, Blood Protein Disorders, +11 more
Locations
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Allergy Associates of the Palm Beaches North Palm Beach, Florida, United States
  • Family Allergy & Asthma Center, PC Atlanta, Georgia, United States
  • Rush University Chicago, Illinois, United States
View all 15 locations
View Trial Details
Completed

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

NCT03907241

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Octapharma Research Site Irvine, California, United States
  • Octapharma Research Site San Diego, California, United States
  • Octapharma Research Site Centennial, Colorado, United States
  • Octapharma Research Site Papillion, Nebraska, United States
View Trial Details
Completed

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

NCT02806986

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Immune System Diseases, +3 more
Locations
  • Wesley Medical Research Auchenflower, Australia
  • Royal Melbourne Hospital Parkville, Australia
  • University Hospital Hradec Králové, Czechia
  • CHU de Montpellier Montpellier, France
View all 23 locations
View Trial Details

Related conditions